Avanza Fonder AB Takes Position in 10x Genomics, Inc. (NASDAQ:TXG)

Avanza Fonder AB acquired a new position in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 65,816 shares of the company's stock, valued at approximately $945,000. Avanza Fonder AB owned approximately 0.05% of 10x Genomics at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Mirador Capital Partners LP lifted its stake in 10x Genomics by 39.2% during the 4th quarter. Mirador Capital Partners LP now owns 80,983 shares of the company's stock valued at $1,163,000 after acquiring an additional 22,792 shares during the period. Assenagon Asset Management S.A. acquired a new position in 10x Genomics during the fourth quarter valued at $26,308,000. Green Alpha Advisors LLC purchased a new stake in 10x Genomics in the fourth quarter valued at $355,000. Diversified Trust Co acquired a new stake in 10x Genomics during the 4th quarter worth about $511,000. Finally, JPMorgan Chase & Co. lifted its holdings in shares of 10x Genomics by 355.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 355,488 shares of the company's stock valued at $8,027,000 after buying an additional 277,355 shares during the period. 84.68% of the stock is currently owned by hedge funds and other institutional investors.

10x Genomics Stock Down 0.1 %

NASDAQ:TXG traded down $0.01 on Monday, reaching $15.08. The company's stock had a trading volume of 1,324,480 shares, compared to its average volume of 1,475,648. The stock has a 50 day moving average price of $14.96 and a 200 day moving average price of $17.95. The firm has a market cap of $1.83 billion, a price-to-earnings ratio of -9.86 and a beta of 1.83. 10x Genomics, Inc. has a 12-month low of $12.95 and a 12-month high of $51.22.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its quarterly earnings data on Tuesday, October 29th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.04. The firm had revenue of $151.65 million for the quarter, compared to the consensus estimate of $158.84 million. 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. The company's quarterly revenue was down 1.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.51) EPS. Equities research analysts expect that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on TXG shares. Citigroup dropped their target price on 10x Genomics from $35.00 to $23.00 and set a "buy" rating on the stock in a report on Wednesday, October 30th. Stephens reaffirmed an "overweight" rating and set a $30.00 target price on shares of 10x Genomics in a report on Thursday, October 10th. Barclays decreased their target price on shares of 10x Genomics from $21.00 to $19.00 and set an "overweight" rating for the company in a research note on Friday, November 1st. UBS Group dropped their price target on shares of 10x Genomics from $25.00 to $20.00 and set a "neutral" rating on the stock in a research report on Wednesday, October 30th. Finally, Morgan Stanley dropped their target price on 10x Genomics from $30.00 to $28.00 and set an "overweight" rating on the stock in a research report on Monday, January 13th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, 10x Genomics presently has an average rating of "Moderate Buy" and a consensus price target of $23.86.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.